A2 BIO
Live / Applied — Fourth extension granted (statement of use) (as of 13 Feb 2026)
What this means for you
Not registered yet, but its 15 Feb 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97796903
- Mark type
- Stylized text
- Filed
- 15 Feb 2023
- Published for opposition
- 26 Dec 2023
- Attorney of record
- Joi A. White
Goods and services
- Class 005 — Pharmaceuticals: Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; biotherapeutics for the treatment and prevention of inflammation and inflammatory diseases; medicines for the treatment and prevention of inflammation and inflammatory diseases; pharmaceutical products for the treatment and prevention of inflammation and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of inflammation and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of inflammation and inflammatory diseases; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases
- Class 040 — Treatment of materials: Manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases using biological cells in the manufacturing process; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of inflammation and inflammatory disease
- Class 042 — Scientific and technological services: Identification and development of therapeutic targets for others for the treatment and prevention of inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of inflammation, and inflammatory diseases; providing scientific information relating to treatment and prevention of inflammation and inflammatory diseases
Owner
- A2 Biotherapeutics, Inc., Agoura Hills, CA, US
- A2 Biotherapeutics, Inc., Agoura Hills, CA, US
Prosecution history
- 13 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Feb 2026 — SOU EXTENSION 4 GRANTED
- 09 Feb 2026 — SOU EXTENSION 4 FILED
- 10 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Aug 2025 — CORRECTED NOA E-MAILED
- 25 Aug 2025 — SOU EXTENSION 3 GRANTED
- 11 Aug 2025 — SOU EXTENSION 3 FILED
- 25 Aug 2025 — DIVISIONAL PROCESSING COMPLETE
- 08 May 2025 — DIVISIONAL REQUEST RECEIVED
- 08 May 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 12 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Aug 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 20 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Feb 2025 — SOU EXTENSION 2 GRANTED